ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Clinical manifestations of Staphylococcus aureus infection in adults

Clinical manifestations of Staphylococcus aureus infection in adults
Literature review current through: Jan 2024.
This topic last updated: Dec 14, 2023.

INTRODUCTION — Staphylococcus aureus is an important pathogen responsible for a broad range of clinical manifestations ranging from relatively benign skin infections to life-threatening conditions such as endocarditis and osteomyelitis. It is also a commensal bacterium colonizing up to two-thirds of the human population, depending upon patient characteristics, technical methods of identifying S. aureus, and body sites [1,2].

Changes in the predominant circulating clones of S. aureus in a population can influence clinical presentations over time [3]. Two major shifts in S. aureus epidemiology have occurred since the 1990s: an epidemic of community-associated skin and soft tissue infections (largely driven by specific methicillin-resistant S. aureus [MRSA] strains), and an increase in the number of health care-associated infections (especially infective endocarditis and prosthetic device infections).

The clinical manifestations of S. aureus infection will be reviewed here. The clinical approach to S. aureus bacteremia is discussed separately. (See "Clinical approach to Staphylococcus aureus bacteremia in adults".)

Issues related to MRSA are also discussed separately. (See "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Epidemiology" and "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections" and "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia".)

CLINICAL MANIFESTATIONS

Skin and soft tissue infection — Skin and soft tissue infections due to S. aureus include:

Impetigo (infection of the epidermis) (see "Impetigo")

Folliculitis (infection of the superficial dermis) (see "Infectious folliculitis")

Furuncles, carbuncles, and abscess (infection of the deep dermis) (see "Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis")

Hidradenitis suppurativa (follicular infection of intertriginous areas) (see "Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis")

Cellulitis, erysipelas, and fasciitis (infection of the subcutaneous tissues) (see "Necrotizing soft tissue infections" and "Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis")

Pyomyositis (infection of skeletal muscle) (see "Primary pyomyositis")

Mastitis (see "Nonlactational mastitis in adults")

Surgical site infections (see "Antimicrobial prophylaxis for prevention of surgical site infection in adults")

S. aureus is the most common pathogen isolated from purulent cellulitis, cutaneous abscesses, and surgical site infections [4,5]. Superficial skin and soft tissue infections caused by S. aureus generally present with purulence or abscess; the diagnosis of S. aureus is established by culture of purulent material. Management may consist of local wound care, debridement, and antibiotics (see related topics).

Bacteremia — S. aureus bacteremia is defined as positive blood cultures for S. aureus; frequently, this occurs in association with correlating symptoms such as fever or hypotension. S. aureus is a leading cause of community-acquired and hospital-acquired bacteremia. Bacteremia may develop as a complication of a primary S. aureus infection such as skin and soft tissue infection, bone and joint infection, or pneumonia. Vascular catheters are a common source of bacteremia. Bacteremia may also lead to subsequent S. aureus infection at a previously sterile site, such as endocarditis or prosthetic device infection [6,7].

The clinical approach to evaluation of patients with S. aureus bacteremia is discussed in detail separately. (See "Clinical approach to Staphylococcus aureus bacteremia in adults" and "Staphylococcus aureus bacteremia in children: Management and outcome".)

Infective endocarditis — S. aureus is the most common cause of infective endocarditis (IE) in resource-rich settings [8-10]. The incidence of IE in the setting of S. aureus bacteremia is 10 to 15 percent [11-17]; however, studies examining the frequency of IE among patients with S. aureus bacteremia have been impacted by sampling bias. The likelihood of IE is related to the circumstances of bacteremia; community-acquired bacteremia is likely to be detected later and therefore more likely to be associated with complications than health care-associated bacteremia.

Risk factors for IE in the setting of S. aureus bacteremia include [12,18-21]:

Prosthetic heart valve

Cardiac implantable electronic device (CIED), such as permanent pacemaker or implantable cardioverter defibrillator

Predisposing cardiac abnormalities

Injection drug use

Intravascular catheter infection

Bacteremia of unclear origin

Persistent bacteremia

IE due to S. aureus can be more severe than IE due to other organisms, including more frequent association with severe sepsis (39 versus 6 percent), major neurological events (18 versus 8 percent), multiorgan failure (29 versus 10 percent), and higher mortality (34 versus 10 percent) [22]. (See "Complications and outcome of infective endocarditis".)

Cardiac device infection — Patients with a CIED who develop S. aureus bacteremia are at increased risk for endocarditis and/or infection involving the device. Among 33 patients with CIEDs who developed S. aureus bacteremia in one series, the rate of device infection was 45 percent [23]; in a later cohort including 152 patients with S. aureus bacteremia at the same institution the rate of device infection was 55 percent [24]. (See "Infections involving cardiac implantable electronic devices: Epidemiology, microbiology, clinical manifestations, and diagnosis".)

Intravascular catheter infection — The presence of an indwelling intravascular catheter is a risk factor for development of S. aureus bacteremia, and onset of S. aureus bacteremia in the setting of an indwelling intravascular catheter should prompt evaluation for catheter-associated infection. (See "Intravascular catheter-related infection: Epidemiology, pathogenesis, and microbiology" and "Intravascular non-hemodialysis catheter-related infection: Clinical manifestations and diagnosis".)

Septic thrombophlebitis can occur in the setting of intravascular catheter infection. Clinical manifestations include venous congestion (eg, venous distension or asymmetric swelling of the extremities). (See "Catheter-related septic thrombophlebitis".)

Sepsis and toxic shock syndrome — Manifestations of staphylococcal toxic shock syndrome include fever, hypotension, and dermatologic manifestations. (See "Staphylococcal toxic shock syndrome".)

Splenic abscess — Splenic abscess is an infrequent complication of staphylococcal bacteremia and/or endocarditis [25-29]. Clinical manifestations include left upper quadrant pain (with or without splenomegaly) and fever (which may be recurrent or persistent despite appropriate antimicrobial therapy) [25]. (See "Splenomegaly and other splenic disorders in adults", section on 'Abscess and infarction'.)

Bone and joint infection — S. aureus is the most common pathogen causing osteomyelitis, septic arthritis, and prosthetic joint infection [4]. Development of back or joint pain should raise the suspicion of an occult site of infection in patients with current or recent S. aureus bacteremia.

Osteomyelitis — Osteomyelitis develops via one of two mechanisms: hematogenously (in the setting of S. aureus bacteremia) or secondary to a contiguous focus of infection. (See "Nonvertebral osteomyelitis in adults: Clinical manifestations and diagnosis".)

In adults, hematogenous osteomyelitis most commonly presents in the form of vertebral involvement [30]. In one series including 309 patients with hematogenous S. aureus osteomyelitis, vertebral osteomyelitis and/or discitis occurred most frequently among patients >50 years with community-acquired bacteremia and no evident inciting source [30]. Epidural abscess may accompany vertebral osteomyelitis. (See "Vertebral osteomyelitis and discitis in adults" and "Spinal epidural abscess".)

Prosthetic joint infection — The mechanism for development of prosthetic joint infection (PJI) depends on the timeframe for onset of symptoms. Early (<3 months after surgery) and delayed infections (3 to 12 months after surgery) are mostly acquired during implantation, whereas late infections (>12 months after surgery) are primarily due to hematogenous seeding. (See "Prosthetic joint infection: Epidemiology, microbiology, clinical manifestations, and diagnosis".)

In a prospective series of 80 patients with orthopedic devices and S. aureus bacteremia, the rate of hematogenous seeding was 34 percent [31]. One retrospective study including 85 patients (143 arthroplasties) noted that hematogenous infection of at least one prosthetic joint occurred in 41 percent of patients; infection was community acquired in all cases [32]. The risk of PJI was greatest in patients with multiple arthroplasties and in patients who had undergone arthroplasty revision. The risk of PJI was twice as high for knee arthroplasties compared with hip arthroplasties (35 versus 19 percent). Asymptomatic infection was very rare, occurring in only one patient.

Septic arthritis or bursitis — Most cases of septic arthritis arise via hematogenous spread of bacteria to the joint; the joint is particularly susceptible to hematogenous infection because the joint space synovium is a highly vascular tissue without a basement membrane. Other mechanisms include trauma, direct inoculation of bacteria during joint surgery, or extension of bony infection into the joint space. (See "Septic arthritis in adults".)

Septic bursitis arises as a result of direct inoculation via bursa puncture or via contiguous spread from adjacent skin or soft tissue infection. (See "Septic bursitis".)

Pulmonary infection — Pulmonary infection due to S. aureus can occur among individuals with S. aureus colonization of the skin or nares, either in the community or in a hospital setting (particularly in the context of intubation or other respiratory tract instrumentation). S. aureus pneumonia can also occur following viral pneumonia or in the setting of right-sided endocarditis with pulmonary emboli. (See "Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults", section on 'S. aureus' and "Overview of pulmonary disease in people who inject drugs" and "Seasonal influenza in adults: Clinical manifestations and diagnosis", section on 'Pneumonia'.)

Meningitis — S. aureus meningitis most commonly occurs in the setting of head trauma or neurosurgery; less commonly, it can also occur as a complication of S. aureus bacteremia [33-35]. (See "Treatment of bacterial meningitis caused by specific pathogens in adults", section on 'Staphylococcus aureus'.)

Bacteriuria — Bacteriuria due to S. aureus can occur via ascending infection in the presence of a urinary catheter or in the setting of S. aureus bacteremia. In the absence of systemic signs of infection, S. aureus bacteriuria associated with the presence of a urinary catheter does not warrant routine investigation for bacteremia; catheter and antibiotic management are discussed in detail separately. (See "Catheter-associated urinary tract infection in adults".)

S. aureus bacteriuria in the absence of a urinary catheter may be an indicator of S. aureus bacteremia [36-40]; blood cultures should be obtained together with clinical evaluation for signs and symptoms of a metastatic or occult staphylococcal infection, particularly if there are other clinical clues of infection such as fever, leukocytosis, or localizing symptoms such as back pain. In one retrospective study including 2054 patients with S. aureus bacteriuria, S. aureus bacteremia was diagnosed within 3 months in 6.9 percent of cases [41].

Other manifestations — Other manifestations of S. aureus infection include:

Foodborne illness – Toxin elaborated by S. aureus is ingested with the contaminated dish, and disease follows shortly thereafter in the form of nausea and vomiting. (See "Causes of acute infectious diarrhea and other foodborne illnesses in resource-abundant settings", section on 'Vomiting'.)

Waterhouse-Friderichsen syndrome – Waterhouse-Friderichsen syndrome (characterized by petechial rash, coagulopathy, cardiovascular collapse, and adrenal hemorrhage) is usually associated with fulminant meningococcemia. It has also been described in the setting of sepsis due to Streptococcus pneumoniae, Neisseria gonorrhoeae, Escherichia coli, and Haemophilus influenzae. Reports of a syndrome of fatal severe sepsis in children caused by S. aureus, both methicillin-sensitive S. aureus and community-associated methicillin-resistant S. aureus, suggest that S. aureus may also be an etiologic agent [42-45]. (See "Clinical manifestations of meningococcal infection".)

Immunoglobulin A vasculitis (IgAV; Henoch-Schönlein purpura [HSP]) – A case report and review of the literature identified 14 cases of IgAV (HSP) associated with S. aureus infection [46]. S. aureus superantigen action on T cells may have caused the autoimmune phenomenon. (See "IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis".)

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Management of Staphylococcus aureus infection".)

SUMMARY

Staphylococcus aureus is a frequent colonizer of the skin and mucosa and can cause a broad range of clinical manifestations. Risk factors for complications of S. aureus infection include community acquisition of bacteremia, presence of a prosthetic device, and underlying medical conditions including immunosuppression. (See 'Introduction' above.)

Clinical manifestations of S. aureus infection include skin and soft tissue infection, bacteremia, and associated conditions (including infective endocarditis, cardiac device infection, intravascular catheter infection, and toxic shock syndrome). (See 'Clinical manifestations' above.)

Bacteremia may develop as a complication of a primary S. aureus infection (such as skin and soft tissue infection). Bacteremia may also lead to subsequent S. aureus infection at a previously sterile site (such as vertebral osteomyelitis). (See 'Bacteremia' above.)

Development of back or joint pain should raise the suspicion of an occult site of infection in patients with current or recent S. aureus bacteremia. In adults, hematogenous osteomyelitis most commonly presents in the form of vertebral involvement. (See 'Bone and joint infection' above.)

Pulmonary infection due to S. aureus can occur among individuals with S. aureus colonization of the skin or nares, either in the community or in a hospital setting (particularly in the context of intubation or other respiratory tract instrumentation). S. aureus pneumonia can also occur following viral pneumonia or in the setting of right-sided endocarditis with pulmonary emboli. (See 'Pulmonary infection' above.)

S. aureus bacteriuria in the absence of a urinary catheter may be an indicator of S. aureus bacteremia. (See 'Bacteriuria' above.)

  1. Russakoff B, Wood C, Lininger MR, et al. A Quantitative Assessment of Staphylococcus aureus Community Carriage in Yuma, Arizona. J Infect Dis 2023; 227:1031.
  2. Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis 2006; 193:172.
  3. Souli M, Ruffin F, Choi SH, et al. Changing Characteristics of Staphylococcus aureus Bacteremia: Results From a 21-Year, Prospective, Longitudinal Study. Clin Infect Dis 2019; 69:1868.
  4. Tong SY, Davis JS, Eichenberger E, et al. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 2015; 28:603.
  5. Turner NA, Sharma-Kuinkel BK, Maskarinec SA, et al. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nat Rev Microbiol 2019; 17:203.
  6. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520.
  7. Fowler VG Jr, Justice A, Moore C, et al. Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40:695.
  8. Fowler VG Jr, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005; 293:3012.
  9. Vogkou CT, Vlachogiannis NI, Palaiodimos L, Kousoulis AA. The causative agents in infective endocarditis: a systematic review comprising 33,214 cases. Eur J Clin Microbiol Infect Dis 2016; 35:1227.
  10. DeSimone DC, Lahr BD, Anavekar NS, et al. Temporal Trends of Infective Endocarditis in Olmsted County, Minnesota, Between 1970 and 2018: A Population-Based Analysis. Open Forum Infect Dis 2021; 8:ofab038.
  11. Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163:2066.
  12. Gopal AK, Fowler VG Jr, Shah M, et al. Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancy. J Clin Oncol 2000; 18:1110.
  13. Chang FY, MacDonald BB, Peacock JE Jr, et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003; 82:322.
  14. Abraham J, Mansour C, Veledar E, et al. Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S aureus and methicillin-resistant S aureus bacteremia. Am Heart J 2004; 147:536.
  15. Fowler VG Jr, Li J, Corey GR, et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol 1997; 30:1072.
  16. Sullenberger AL, Avedissian LS, Kent SM. Importance of transesophageal echocardiography in the evaluation of Staphylococcus aureus bacteremia. J Heart Valve Dis 2005; 14:23.
  17. Holland TL, Arnold C, Fowler VG Jr. Clinical management of Staphylococcus aureus bacteremia: a review. JAMA 2014; 312:1330.
  18. Fang G, Keys TF, Gentry LO, et al. Prosthetic valve endocarditis resulting from nosocomial bacteremia. A prospective, multicenter study. Ann Intern Med 1993; 119:560.
  19. El-Ahdab F, Benjamin DK Jr, Wang A, et al. Risk of endocarditis among patients with prosthetic valves and Staphylococcus aureus bacteremia. Am J Med 2005; 118:225.
  20. Hill EE, Vanderschueren S, Verhaegen J, et al. Risk factors for infective endocarditis and outcome of patients with Staphylococcus aureus bacteremia. Mayo Clin Proc 2007; 82:1165.
  21. Le Moing V, Alla F, Doco-Lecompte T, et al. Staphylococcus aureus Bloodstream Infection and Endocarditis--A Prospective Cohort Study. PLoS One 2015; 10:e0127385.
  22. Nadji G, Rémadi JP, Coviaux F, et al. Comparison of clinical and morphological characteristics of Staphylococcus aureus endocarditis with endocarditis caused by other pathogens. Heart 2005; 91:932.
  23. Chamis AL, Peterson GE, Cabell CH, et al. Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. Circulation 2001; 104:1029.
  24. Maskarinec SA, Thaden JT, Cyr DD, et al. The Risk of Cardiac Device-Related Infection in Bacteremic Patients Is Species Specific: Results of a 12-Year Prospective Cohort. Open Forum Infect Dis 2017; 4:ofx132.
  25. Robinson SL, Saxe JM, Lucas CE, et al. Splenic abscess associated with endocarditis. Surgery 1992; 112:781.
  26. Ting W, Silverman NA, Arzouman DA, Levitsky S. Splenic septic emboli in endocarditis. Circulation 1990; 82:IV105.
  27. Ebright JR, Alam E, Ahmed H, et al. Splenic infarction and abscess in the setting of infective endocarditis. Infect Dis Clin Pract 2007; 15:17.
  28. Hasan LZ, Shrestha NK, Dang V, et al. Surgical infective endocarditis and concurrent splenic abscess requiring splenectomy: a case series and review of the literature. Diagn Microbiol Infect Dis 2020; 97:115082.
  29. Radcliffe C, Tang Z, Gisriel SD, Grant M. Splenic Abscess in the New Millennium: A Descriptive, Retrospective Case Series. Open Forum Infect Dis 2022; 9:ofac085.
  30. Espersen F, Frimodt-Møller N, Thamdrup Rosdahl V, et al. Changing pattern of bone and joint infections due to Staphylococcus aureus: study of cases of bacteremia in Denmark, 1959-1988. Rev Infect Dis 1991; 13:347.
  31. Murdoch DR, Roberts SA, Fowler Jr VG Jr, et al. Infection of orthopedic prostheses after Staphylococcus aureus bacteremia. Clin Infect Dis 2001; 32:647.
  32. Tande AJ, Palraj BR, Osmon DR, et al. Clinical Presentation, Risk Factors, and Outcomes of Hematogenous Prosthetic Joint Infection in Patients with Staphylococcus aureus Bacteremia. Am J Med 2016; 129:221.e11.
  33. Pintado V, Meseguer MA, Fortún J, et al. Clinical study of 44 cases of Staphylococcus aureus meningitis. Eur J Clin Microbiol Infect Dis 2002; 21:864.
  34. Jensen AG, Espersen F, Skinhøj P, et al. Staphylococcus aureus meningitis. A review of 104 nationwide, consecutive cases. Arch Intern Med 1993; 153:1902.
  35. Aguilar J, Urday-Cornejo V, Donabedian S, et al. Staphylococcus aureus meningitis: case series and literature review. Medicine (Baltimore) 2010; 89:117.
  36. Lee BK, Crossley K, Gerding DN. The association between Staphylococcus aureus bacteremia and bacteriuria. Am J Med 1978; 65:303.
  37. Sheth S, DiNubile MJ. Clinical significance of staphylococcus aureus bacteriuria without concurrent bacteremia. Clin Infect Dis 1997; 24:1268.
  38. Muder RR, Brennen C, Rihs JD, et al. Isolation of Staphylococcus aureus from the urinary tract: association of isolation with symptomatic urinary tract infection and subsequent staphylococcal bacteremia. Clin Infect Dis 2006; 42:46.
  39. Anderson DJ, Kaye KS, Sexton DJ. Methicillin-resistant Staphylococcus aureus bacteremia after isolation from urine. Clin Infect Dis 2006; 42:1504.
  40. Schuler F, Barth PJ, Niemann S, Schaumburg F. A Narrative Review on the Role of Staphylococcus aureus Bacteriuria in S. aureus Bacteremia. Open Forum Infect Dis 2021; 8:ofab158.
  41. Stokes W, Parkins MD, Parfitt ECT, et al. Incidence and Outcomes of Staphylococcus aureus Bacteriuria: A Population-based Study. Clin Infect Dis 2019; 69:963.
  42. Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med 2005; 353:1245.
  43. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998; 279:593.
  44. Centers for Disease Control and Prevention (CDC). Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus — Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep 1999; 48:707.
  45. Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003; 37:1050.
  46. Eftychiou C, Samarkos M, Golfinopoulou S, et al. Henoch-Schonlein purpura associated with methicillin-resistant Staphylococcus aureus infection. Am J Med 2006; 119:85.
Topic 2135 Version 33.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟